ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -35 مورد

Bortezomib: Drug information

Bortezomib: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Bortezomib: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Boruzu;
  • Velcade
Brand Names: Canada
  • ACT Bortezomib;
  • Bortezomib SDZ;
  • PMS-Bortezomib;
  • TARO-Bortezomib;
  • Velcade
Pharmacologic Category
  • Antineoplastic Agent, Proteasome Inhibitor
Dosing: Adult

Dosage guidance:

Dosing: Consecutive doses should be separated by at least 72 hours.

Dosage form information: The reconstituted concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose.

Clinical considerations: Consecutive doses should be separated by at least 72 hours. Consider antiviral prophylaxis for herpes virus infection during therapy. Consider initiating via the SUBQ route in patients at risk for or with preexisting neuropathy (Ref).

Antibody-mediated rejection, treatment

Antibody-mediated rejection, treatment (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen.

Cardiac transplantation (off-label use): IV: 1.3 to 1.5 mg/m2 typically given on days 1, 4, 8, and 11 (treatment frequency varies) for a total of 4 doses (treatment duration may vary) (Ref).

Kidney transplantation (off-label use): Note: Use in patients with early antibody-mediated rejection; benefit is not demonstrated in patients with late antibody-mediated rejection (Ref).

IV, SUBQ: 1.3 mg/m2 every 3 to 4 days for 4 doses; administer after plasmapheresis (Ref).

Liver transplantation (off-label use): IV, SUBQ: 1.3 mg/m2 once to twice weekly for up to 4 doses (Ref).

Lung transplantation (off-label use): IV, SUBQ: 1.3 mg/m2 once every 3 to 4 days for a total of 4 doses (Ref).

Cutaneous T-cell lymphoma, mycosis fungoides, relapsed or refractory

Cutaneous T-cell lymphoma, mycosis fungoides, relapsed or refractory (off-label use): IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 6 cycles (Ref).

Desensitization, kidney transplantation

Desensitization, kidney transplantation (adjunctive) (off-label use): Note: Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen (eg, following intravenous immunoglobulin and rituximab). Appropriate antiviral and antimicrobial prophylaxis should be employed during and following treatment (Ref).

Kidney transplantation (off-label use): IV: 1.3 mg/m2 every 3 days for 4 doses (Ref).

Follicular lymphoma, relapsed or refractory

Follicular lymphoma, relapsed or refractory (off-label use): IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with bendamustine and rituximab) for 6 cycles (Ref) or 1.6 mg/m2 on days 1, 8, 15, and 22 of a 35-day treatment cycle, in combination with bendamustine and rituximab for 5 cycles (Ref).

Mantle cell lymphoma, previously untreated

Mantle cell lymphoma, previously untreated (first-line therapy): Note: Platelets should be ≥100,000/mm3, ANC should be ≥1,500/mm3, hemoglobin should be ≥8 g/dL, and nonhematologic toxicities should resolve to grade 1 or baseline prior to each cycle (cycle 2 and beyond).

VR-CAP (or VcR-CAP) regimen: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle for 6 cycles (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone). If response first documented at cycle 6, treatment for an additional 2 cycles is recommended (Ref).

Mantle cell lymphoma, relapsed

Mantle cell lymphoma, relapsed: IV, SUBQ: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 17 cycles or for 4 cycles beyond initial complete response; discontinue for disease progression or unacceptable toxicity (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with bendamustine and rituximab) for 6 cycles (Ref).

Multiple myeloma, previously untreated

Multiple myeloma, previously untreated (first-line therapy): Note: Bortezomib regimens also containing melphalan should be avoided in patients who are potential candidates for hematopoietic cell transplantation (Ref).

VMP regimen: Note: Platelets should be ≥70,000/mm3, ANC should be ≥1,000/mm3, and nonhematologic toxicities should resolve to grade 1 or baseline prior to initiation of any cycle of therapy. IV, SUBQ: 1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day treatment cycle for 4 cycles, followed by 1.3 mg/m2 on days 1, 8, 22, and 29 of a 42-day treatment cycle for 5 cycles (in combination with melphalan and prednisone). Retreatment may be considered for patients who had previously responded to bortezomib (either as monotherapy or in combination) and who have relapsed at least 6 months after completing prior bortezomib therapy; initiate at the last tolerated dose (Ref).

First- line therapy, other dosing/combinations: Note: Refer to protocol for dosage adjustment details.

VRd (or RVd) regimen: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for 8 cycles (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for up to 8 induction cycles, followed by 1.3 mg/m2 on days 1, 8, 15, and 22 of a 42-day treatment cycle (as a single agent) for 4 maintenance cycles (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for 3 cycles, followed by conditioning/transplant, followed (after hematologic recovery in patients without progression) by 1.3 mg/m2 (or last tolerated dose from cycle 3) on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for 2 cycles (Ref).

VRd (or RVd) regimen: SUBQ: 1.3 mg/m2 on days 1, 8, 15, and 22 of a 35-day treatment cycle (in combination with lenalidomide and dexamethasone) for 9 induction cycles, followed by 1.3 mg/m2 (or last tolerated dose from cycle 9) on days 1 and 15 of a 28-day treatment cycle (in combination with lenalidomide) for 6 consolidation cycles (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with lenalidomide and dexamethasone) for 6 induction cycles (with mobilization after the third induction cycle), followed by conditioning/transplant, followed by 2 additional consolidation cycles 3 months after transplant (Ref).

VTd regimen: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle for 3 induction cycles (in combination with thalidomide and dexamethasone), followed by tandem transplant, followed by 1.3 mg/m2 on days 1, 8, 15, and 22 every 35 days for 2 consolidation cycles (in combination with thalidomide and dexamethasone) beginning 3 months after second transplant (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with thalidomide and dexamethasone) for 6 induction cycles followed by hematopoietic cell transplant and maintenance (Ref).

VTd regimen: SUBQ: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with thalidomide and dexamethasone) for 4 induction cycles, followed by conditioning/transplant (Ref).

CyBorD (or VCd) regimen: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with cyclophosphamide and dexamethasone), for up to 8 induction cycles followed by 1.3 mg/m2 on days 1, 8, 15, and 22 of a 42-day treatment cycle (as a single agent) for 4 maintenance cycles (Ref) or 1.3 mg/m2 on days 1, 4, 8, 11 of a 28-day treatment cycle (in combination with cyclophosphamide and dexamethasone) for up to 4 cycles (Ref) or 1.5 mg/m2 on days 1, 8, 15, and 22 of a 28-day treatment cycle for 4 cycles (may continue beyond 4 cycles) in combination with cyclophosphamide and dexamethasone (Ref).

PAD regimen: IV: Induction: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with doxorubicin and dexamethasone) for 3 cycles, followed by conditioning/transplantation, and then maintenance bortezomib 1.3 mg/m2 once every 2 weeks for 2 years (Ref).

Daratumumab-containing regimens: SUBQ: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle (in combination with daratumumab, lenalidomide, and dexamethasone; DVRd regimen) for 4 induction cycles and 2 post-transplant consolidation cycles (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day cycle (in combination with daratumumab, thalidomide, and dexamethasone; DVTd regimen) for up to 4 pretransplant induction cycles and 2 posttransplant consolidation cycles (Ref) or 1.3 mg/m2 two times a week during weeks 1, 2, 4, and 5 of the first 6-week cycle (cycle 1; 8 doses/cycle), followed by 1.3 mg/m2 once a week during weeks 1, 2, 4, and 5 for eight 6-week cycles (cycles 2 to 9; 4 doses/cycle) in combination with daratumumab, melphalan, and prednisone; after cycle 9, daratumumab is continued as a single agent (Ref).

VD regimen: IV: Induction: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with dexamethasone) for 4 cycles, followed by autologous cell transplantation (Ref).

VTD-PACE regimen:

Induction: SUBQ: 1 mg/m2 on days 1, 4, 8, and 11 (in combination with thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) for 2 cycles administered ≤8 weeks apart, followed by autologous hematopoietic cell transplant (HCT) (Ref).

Consolidation: SUBQ: 1 mg/m2 on days 1, 4, 8, and 11 (in combination with thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) for 2 cycles. Consolidation cycle 1 is to begin 6 weeks to 4 months following last autologous HCT and cycle 2 is to begin 2 to 4 months following cycle 1 (Ref).

Maintenance: SUBQ: 1 mg/m2 on days 1, 4, 8, and 11 of a 28-day cycle (in combination with thalidomide and dexamethasone) for 1 year. Maintenance is to begin 1 to 4 months following cycle 2 of consolidation (Ref).

Patients ≥65 years of age: IV: 1.3 mg/m2 on days 1, 8, 15, and 22 of a 35-day treatment cycle for 9 cycles, in combination with either melphalan and prednisone or melphalan, prednisone, and thalidomide (Ref).

Maintenance therapy in transplant-eligible patients (following induction and transplant; in patients intolerant to or unable to receive maintenance therapy with lenalidomide): IV: 1.3 mg/m2 once every 2 weeks for 2 years (Ref). For high-risk patients, maintenance therapy with a proteosome inhibitor ± lenalidomide may be considered (Ref).

Multiple myeloma, relapsed or refractory

Multiple myeloma, relapsed or refractory:

Single-agent therapy: IV, SUBQ: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle. Therapy extending beyond 8 cycles may be administered by the standard schedule or may be given once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest (days 23 through 35). Retreatment may be considered for patients who had previously responded to bortezomib (either as monotherapy or in combination) and who have relapsed at least 6 months after completing prior bortezomib therapy; initiate at the last tolerated dose. Administer twice weekly for 2 weeks on days 1, 4, 8, and 11 of a 21-day treatment cycle (either as a single agent or in combination with dexamethasone) for a maximum of 8 cycles (Ref).

Relapsed or refractory disease, other dosing/combinations: Note: Refer to protocol for dosage adjustment details.

VRd (or RVd) regimen: IV: 1 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with lenalidomide and dexamethasone) for up to 8 cycles, followed by maintenance therapy (if response or stable disease) of 1 mg/m2 (or the dose tolerated in cycle 8) on days 1 and 8 of a 21-day treatment cycle (± lenalidomide and/or dexamethasone) until disease progression or unacceptable toxicity (Ref).

DVd regimen: SUBQ: 1.3 mg/m2 on days 1, 4, 8, and 11 every 21 days (in combination with daratumumab and dexamethasone) for up to 8 cycles (Ref).

VPd regimen: IV, SUBQ: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with pomalidomide and dexamethasone) for 8 cycles, followed by 1.3 mg/m2 on days 1 and 8 of a 21-day treatment cycle (in combination with pomalidomide and dexamethasone) until disease progression or unacceptable toxicity (Ref).

SVd regimen: SUBQ: 1.3 mg/m2 on days 1, 8, 15, and 22 every 35 days (in combination with selinexor and dexamethasone) until disease progression or unacceptable toxicity (Ref).

Bortezomib/Doxorubicin (liposomal) regimen: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with liposomal doxorubicin) for at least 8 cycles or until disease progression or unacceptable toxicity (Ref).

CyBorD (or VCD) regimen: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 8 cycles, followed by 1.3 mg/m2 on days 1, 8, 15, and 22 of a 35-day treatment cycle for up to 3 cycles (in combination with cyclophosphamide and dexamethasone) (Ref).

Bendamustine/Bortezomib/Dexamethasone regimen: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day treatment cycle (in combination with bendamustine and dexamethasone) for 4 cycles (if no response) or for up to a maximum of 8 cycles (Ref).

Peripheral T-cell lymphoma, relapsed/refractory

Peripheral T-cell lymphoma, relapsed/refractory (off-label use): IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 6 cycles (Ref).

Systemic light chain amyloidosis

Systemic light chain amyloidosis (off-label use):

Single-agent therapy: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (with or without dexamethasone) for up to 8 cycles (Ref) or 1.6 mg/m2 on days 1, 8, 15, and 22 of a 35-day cycle for up to 8 cycles (Ref).

Combination therapy: Note: Refer to protocols for dosage adjustment details.

CyBorD (or VCD or CVD) regimen: IV: 1 mg/m2 on days 1, 4, 8, and 11 (in combination with cyclophosphamide and dexamethasone) for a maximum of 8 cycles; bortezomib dose could be increased to 1.3 mg/m2 if well-tolerated (Ref).

Daratumumab-CyBorD (or VCD) regimen: SUBQ: 1.3 mg/m2 on days 1, 8, 15, and 22 of a 28-day cycle (in combination with daratumumab hyaluronidase, cyclophosphamide, and dexamethasone) for 6 cycles (Ref).

Bortezomib/melphalan/dexamethasone regimen: IV or SUBQ: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 28-day cycle (in combination with melphalan and dexamethasone) for 2 cycles, followed by 1.3 mg/m2 on days 1, 8, 15, and 22 of a 35-day cycle (in combination with melphalan and dexamethasone) for 6 additional cycles (Ref).

Waldenström macroglobulinemia

Waldenström macroglobulinemia (off-label use): Note: The Tenth International Workshop on Waldenström Macroglobulinemia prefers administering bortezomib SUBQ (if possible) (IWWM [Castillo 2020]). Refer to protocols for dosage adjustment details.

Initial therapy: IV: 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with dexamethasone and rituximab) for 4 cycles, followed by a 12-week rest, then an additional 4 cycles for a total of 8 cycles (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle for 1 cycle, followed by 1.6 mg/m2 on days 1, 8, 15, and 22 of a 35-day treatment cycle for 4 cycles; cycles 2 and 5 also included dexamethasone and rituximab (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (as a single agent); continue until disease progression or until 2 cycles after achieving a complete response (Ref).

Relapsed or refractory disease: IV: 1.6 mg/m2 on days 1, 8, and 15 of a 28-day treatment cycle for 6 cycles (in combination with rituximab) (Ref) or 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle (as a single agent); continue until disease progression or until 2 cycles after achieving a complete response (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: IV, SUBQ: No dosage adjustment necessary for any degree of kidney impairment (Ref).

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2):

Note: Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

IV, SUBQ: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Dialyzability unknown but likely minimal given large Vd (Ref):

IV, SUBQ: No dosage adjustment is necessary; when scheduled dose falls on a dialysis day, administer after dialysis (Ref).

Peritoneal dialysis: Dialyzability unknown but likely minimal given large Vd (Ref): IV, SUBQ: No dosage adjustment necessary (Ref).

CRRT: IV, SUBQ: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): IV, SUBQ:No dosage adjustment necessary; when scheduled dose falls on a PIRRT day, administer after PIRRT (Ref).

Dosing: Liver Impairment: Adult

Hepatic impairment prior to treatment initiation:

Mild impairment (bilirubin ≤ ULN and AST >ULN or bilirubin >1 to 1.5 times ULN and any AST): No initial dose adjustment is necessary (Ref).

Moderate (bilirubin >1.5 to 3 times ULN and any AST) and severe impairment (bilirubin >3 times ULN and any AST): Reduce initial dose to 0.7 mg/m2 in the first cycle; based on patient tolerance, may consider dose escalation to 1 mg/m2 or further dose reduction to 0.5 mg/m2 in subsequent cycles (Ref).

Acute hepatotoxicity during treatment: Interrupt bortezomib treatment (to assess reversibility) if acute liver failure, hepatitis, increased transaminases, and/or hyperbilirubinemia occur; information on bortezomib rechallenge is limited (Ref).

Dosing: Obesity: Adult

American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m2 : Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI <30 kg/m2; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (Ref).

Dosing: Adjustment for Toxicity: Adult

Note: Hematologic toxicity may also require platelet transfusion, supportive care, and/or myeloid growth factors as clinically indicated.

Multiple myeloma (previously untreated, in combination with melphalan and prednisone): Note: Refer to protocol for specific dosage modifications for melphalan and prednisone.

Bortezomib Recommended Dosage Modifications for Adverse Reactions in Previously Untreated Multiple Myeloma

Adverse reaction

Severity

Bortezomib dosage modification

Hematologic toxicity

Neutropenia

ANC <750/mm3 on bortezomib dosing day (except day 1)

Withhold bortezomib.

If several bortezomib doses in consecutive cycles are withheld due to toxicity, reduce bortezomib dose by one dose level (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose).

Thrombocytopenia

Platelets ≤30,000/mm3 on bortezomib dosing day (except day 1)

Withhold bortezomib.

If several bortezomib doses in consecutive cycles are withheld due to toxicity, reduce bortezomib dose by one dose level (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose).

Nonhematologic toxicity

Other nonhematologic adverse reactions (excluding neuropathy)

≥ Grade 3

Withhold bortezomib until toxicity resolves to grade 1 or baseline; may reinitiate with one dose level reduction (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose).

Mantle cell lymphoma (previously untreated, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone): Note: Refer to protocol for specific dosage modifications for rituximab, cyclophosphamide, doxorubicin, and prednisone.

Bortezomib Recommended Dosage Modifications for Adverse Reactions in Previously Untreated Mantle Cell Lymphoma

Adverse reaction

Severity

Bortezomib dosage modification

Hematologic toxicity

Neutropenia

≥ Grade 3

Withhold bortezomib for up to 2 weeks until ANC ≥750/mm3.

ANC ≥750/mm3 within 2 weeks of interruption: Resume bortezomib with one dose level reduction (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose).

Resolution of ANC ≥750/mm3 does not occur within 2 weeks of interruption: Discontinue bortezomib.

Thrombocytopenia

Platelets <25,000/mm3 on bortezomib dosing day

Withhold bortezomib for up to 2 weeks until platelets ≥25,000/mm3.

Platelets ≥25,000/mm3 within 2 weeks of interruption: Resume bortezomib with one dose level reduction (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose).

Resolution of platelets ≥25,000/mm3 does not occur within 2 weeks of interruption: Discontinue bortezomib.

Nonhematologic toxicity

Other nonhematologic adverse reactions (excluding neuropathy)

≥ Grade 3

Withhold bortezomib until toxicity resolves to ≤grade 2; may reinitiate with one dose level reduction (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose).

Relapsed multiple myeloma and relapsed mantle cell lymphoma: Note: Refer to protocol for specific dosage modifications for other concomitant anticancer therapies.

Bortezomib Recommended Dosage Modifications for Adverse Reactions in Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma

Hematologic toxicity

Grade 4

Withhold until toxicity resolved; may reinitiate with a 25% dose reduction (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose)

Nonhematologic toxicity (excluding neuropathy)

Grade 3

Withhold until toxicity resolved; may reinitiate with a 25% dose reduction (1.3 mg/m2/dose reduced to 1 mg/m2/dose; 1 mg/m2/dose reduced to 0.7 mg/m2/dose)

Other nonhematologic toxicities including neuropathic pain and/or peripheral sensory, motor, or autonomic neuropathy (all indications):

Bortezomib Recommended Dosage Modifications for Adverse Reactions (All Indications)

Adverse reaction

Severity

Bortezomib dosage modification

Nonhematologic toxicity

a PRES = Posterior reversible leukoencephalopathy syndrome; TTP/HUS = Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome

Cardiopulmonary toxicity

Any

Promptly evaluate with new or worsening symptoms; therapy interruption may be required.

GI toxicity

Any

GI symptoms may require antiemetics or antidiarrheals. Administer fluid and electrolytes to prevent dehydration; interrupt therapy for severe symptoms.

Hyper- or hypoglycemia (in patients with diabetes)

Any

May require adjustment of diabetes medications.

Hypotension (orthostatic or postural)

Any

May require adjustment of antihypertensive medication, hydration, and mineralocorticoids and/or sympathomimetics.

Neuropathic pain and/or peripheral sensory, motor, or autonomic neuropathy

Any

Consider SUBQ administration in patients with preexisting or at high risk for peripheral neuropathy.

Grade 1 (asymptomatic; deep tendon reflex loss or paresthesia without pain or loss of function)

No dose modification required.

Grade 1 with pain or

Grade 2 (moderate symptoms; limiting instrumental activities of daily living)

Reduce bortezomib dose to 1 mg/m2.

Grade 2 with pain or

Grade 3 (severe symptoms; limiting self-care activities of daily living)

Withhold bortezomib until toxicity resolves; upon resolution, resume bortezomib at a reduced dose of 0.7 mg/m2.

Grade 4 (life-threatening consequences with urgent intervention indicated and/or severe autonomic neuropathy)

Discontinue bortezomib.

PRESa

Suspected

Evaluate promptly any new onset or worsening neurologic symptoms.

Perform MRI to confirm diagnosis.

Confirmed

Discontinue bortezomib. The safety of reinitiating bortezomib in patients previously experiencing PRES is unknown.

Thrombotic microangiopathy (including TTP/HUSa)

Suspected

Withhold bortezomib and evaluate promptly; may resume bortezomib if diagnosis of TTP/HUS is excluded.

Confirmed

Discontinue bortezomib. The safety of reinitiating bortezomib in patients previously experiencing TTP/HUS is unknown.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

>10%:

Dermatologic: Skin rash (12% to 23%)

Gastrointestinal: Abdominal pain (11%), anorexia (14% to 21%), constipation (24% to 34%), decreased appetite (11%), diarrhea (19% to 52%; grade 3: 1% to 7%; grades ≥3: 7%), nausea (14% to 52%; grade 3: 2%; grades ≥3: 3%), vomiting (9% to 29%; grade 3: 2%; grades ≥3: 3% to 4%)

Hematologic & oncologic: Anemia (12% to 23%; grades ≥3: ≤6%), leukopenia (18% to 20%; grade 3: 5%; grade 4: 1%), neutropenia (5% to 27%; grades ≥3%: 2% to 18%), thrombocytopenia (16% to 52%; grades ≥3%: 3% to 28%)

Infection: Herpes zoster infection (herpes zoster infection and reactivation: 6% to 11%)

Nervous system: Asthenia (7% to 16%), dizziness (10% to 18%), fatigue (7% to 52%), headache (10% to 19%), malaise (≤59%), neuralgia (23%), paresthesia (7% to 19%), peripheral neuropathy (including peripheral motor neuropathy, peripheral sensory neuropathy: 28% to 54%; grades ≥2: 24% to 39%; grades ≥3: 6% to 15%; grade 4: <1%)

Respiratory: Dyspnea (11%)

Miscellaneous: Fever (8% to 23%)

1% to 10%:

Cardiovascular: Cardiac disorder (treatment emergent: 8%), cardiogenic shock (≤1%), heart failure (≤1%), hypotension (including orthostatic hypotension: 8% to 9%)

Hematologic & oncologic: Hemorrhage (grades ≥3: 2%)

Infection: Herpes simplex infection (1% to 3%)

Local: Injection-site reaction (6%; including erythema at injection site), irritation at injection site (5%)

Respiratory: Acute pulmonary edema (≤1%), pulmonary edema (≤1%)

Frequency not defined (reported reactions may have occurred with either monotherapy or combination therapy):

Cardiovascular: Acute myocardial infarction, amyloid heart disease, angina pectoris, atrial fibrillation (aggravated), atrial flutter, atrioventricular block, bradycardia, decreased left ventricular ejection fraction, deep vein thrombosis, edema, hypertension, ischemic heart disease, limb embolism, pericardial effusion, pericarditis, peripheral edema, portal vein thrombosis, prolonged QT interval on ECG, pulmonary embolism, sinoatrial arrest, torsades de pointes, ventricular tachycardia

Dermatologic: Pruritus, urticaria

Endocrine & metabolic: Dehydration, hyperkalemia, hypernatremia, hyperuricemia, hypocalcemia, hypokalemia, hyponatremia, weight loss

Gastrointestinal: Acute pancreatitis, cholestasis, duodenitis (hemorrhagic), dysgeusia, dyspepsia, dysphagia, fecal impaction, gastritis (hemorrhagic), gastroenteritis, gastroesophageal reflux disease, hematemesis, intestinal obstruction, intestinal perforation, melena, oral candidiasis, oral mucosal petechiae, paralytic ileus, peritonitis, stomatitis

Genitourinary: Bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, urinary tract infection

Hematologic & oncologic: Disseminated intravascular coagulation, febrile neutropenia, lymphocytopenia

Hepatic: Ascites, hepatic failure, hepatic hemorrhage, hepatitis, hyperbilirubinemia, increased liver enzymes

Hypersensitivity: Facial edema, hypersensitivity angiitis, hypersensitivity reaction (including anaphylaxis, angioedema, type III hypersensitivity reaction)

Infection: Aspergillosis, bacteremia, listeriosis, septic shock, toxoplasmosis

Local: Injection-site phlebitis, pain at injection site

Nervous system: Agitation, anxiety, ataxia, cerebral hemorrhage, cerebrovascular accident, chills, coma, confusion, cranial nerve palsy, dysarthria, dysautonomia, dysesthesia, encephalopathy, insomnia, intracranial hemorrhage, mental status changes, motor dysfunction, paralysis, postherpetic neuralgia, psychosis, seizure (tonic-clonic), spinal cord compression, subdural hematoma, suicidal ideation, transient ischemic attacks, vertigo

Neuromuscular & skeletal: Arthralgia, back pain, bone fracture, limb pain, myalgia, ostealgia

Ophthalmic: Blurred vision, conjunctival infection, diplopia, eye irritation

Otic: Auditory impairment

Renal: Bilateral hydronephrosis, kidney failure (including acute kidney injury, chronic renal failure), nephrolithiasis, proliferative glomerulonephritis

Respiratory: Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, bronchitis, cough, dyspnea on exertion, epistaxis, exacerbation of chronic obstructive pulmonary disease, hemoptysis, hypoxia, interstitial pneumonitis, laryngeal edema, nasopharyngitis, pleural effusion, pneumonia, pneumonitis, pulmonary hypertension, pulmonary infiltrates (including diffuse), respiratory distress, respiratory tract infection, sinusitis

Postmarketing:

Cardiovascular: Cardiac tamponade

Dermatologic: Stevens-Johnson syndrome, Sweet syndrome, toxic epidermal necrolysis

Gastrointestinal: Ischemic colitis

Hematologic & oncologic: Hemolytic-uremic syndrome, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, tumor lysis syndrome

Nervous system: Guillain-Barré syndrome, herpes meningoencephalitis, peripheral demyelinating polyneuropathy, posterior reversible encephalopathy syndrome, progressive multifocal leukoencephalopathy

Ophthalmic: Blepharitis, blindness, chalazion (Ref), ocular herpes simplex, optic neuropathy

Otic: Deafness (bilateral)

Contraindications

Hypersensitivity (excluding local reactions) to bortezomib, boron, boric acid (generic product), glycine (some generic products), mannitol (Velcade, some generic products), or any component of the formulations; administration via the intrathecal route.

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Hematologic toxicity, including grade 3 and 4 neutropenia and thrombocytopenia may occur; risk is increased in patients with pretreatment platelet counts <75,000/mm3. Nadirs generally occur following the last dose of a cycle and recover prior to the next cycle. Hemorrhage (GI and intracerebral) due to low platelet count has been observed. Neutropenic fever has been observed.

• Cardiovascular effects: Acute development or exacerbation of HF and new onset decreased left ventricular ejection fraction (LVEF) have been reported with bortezomib; some cases have occurred in patients without risk factors for HF and/or decreased LVEF. Isolated case of QTc prolongation have been reported with bortezomib.

• GI effects: Nausea, vomiting, diarrhea, constipation, or ileus may occur.

• Hepatotoxicity: Acute liver failure has been reported (rarely) in patients receiving multiple concomitant medications and with serious underlying conditions. Hepatitis, transaminase increases, and hyperbilirubinemia have also been reported. Limited data exist for patients that have been rechallenged.

• Herpes reactivation: Herpes (zoster and simplex) reactivation has been reported with bortezomib.

• Hypersensitivity: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, and laryngeal edema have been reported with bortezomib.

• Hypotension: Bortezomib may cause hypotension (including postural and orthostatic). Patients with a history of syncope, receiving medications associated with hypotension, and those who are dehydrated may be at increased risk of hypotension.

• Peripheral neuropathy: Bortezomib may cause or worsen peripheral neuropathy (usually sensory but may be mixed sensorimotor); risk may be increased with previous use of neurotoxic agents or preexisting peripheral neuropathy (in patients with preexisting neuropathy, use only after risk versus benefit assessment). The incidence of grades 2 and 3 peripheral neuropathy may be lower with SUBQ route (compared to IV). The majority of patients with ≥ grade 2 peripheral neuropathy have improvement in or resolution of symptoms with dose adjustments or discontinuation. In a study of patients ≥65 years of age receiving a weekly bortezomib schedule with combination chemotherapy, the incidence of peripheral neuropathy was significantly reduced without an effect on outcome (Palumbo 2010).

• Posterior reversible leukoencephalopathy syndrome: Posterior reversible leukoencephalopathy syndrome (PRES, formerly RPLS) has been reported (rarely). Symptoms of PRES include confusion, headache, hypertension, lethargy, seizure, blindness and/or other vision, or neurologic disturbances.

• Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy has been rarely observed; symptoms may include confusion, loss of balance, vision disturbances, reduced strength or weakness in an arm/leg.

• Pulmonary toxicity: Pulmonary disorders (some fatal) including pneumonitis, interstitial pneumonia, lung infiltrates, and acute respiratory distress syndrome (ARDS) have been reported. Pulmonary hypertension (without left heart failure or significant pulmonary disease) has been reported rarely.

• Thrombotic microangiopathy: Cases (some fatal) of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported.

• Tumor lysis syndrome: Tumor lysis syndrome has been reported with bortezomib; risk is increased in patients with high tumor burden prior to treatment.

Disease-related concerns:

• Diabetes: Hyper- and hypoglycemia may occur in patients with diabetes receiving oral hypoglycemics.

Other warnings/precautions:

• Appropriate administration: For SUBQ or IV administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should NOT be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location away from the separate storage location recommended for intrathecal medications. Bortezomib should NOT be delivered to the patient at the same time with any medications intended for central nervous system administration. The reconstituted concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose. The manufacturers provide stickers to facilitate identification of the route for reconstituted vials. Some bortezomib products may not be approved for SUBQ administration; refer to specific product labeling for approved administration routes.

Product Availability

Boruzu (bortezomib 3.5 mg/1.4 mL ready-to-use vials): FDA approved September 2024; anticipated availability in the second quarter of 2025. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection [preservative free]:

Boruzu: 3.5 mg/1.4 mL (1.4 mL)

Solution, Intravenous [preservative free]:

Generic: 3.5 mg/1.4 mL (1.4 mL [DSC])

Solution Reconstituted, Injection:

Generic: 3.5 mg (1 ea)

Solution Reconstituted, Injection [preservative free]:

Velcade: 3.5 mg (1 ea)

Generic: 1 mg (1 ea); 2.5 mg (1 ea); 3.5 mg (1 ea)

Solution Reconstituted, Intravenous [preservative free]:

Generic: 3.5 mg (1 ea [DSC])

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Boruzu Injection)

3.5MG/1.4ML (per mL): $765.00

Solution (reconstituted) (Bortezomib Injection)

1 mg (per each): $97.40

2.5 mg (per each): $230.41

3.5 mg (per each): $42.00 - $1,827.42

Solution (reconstituted) (Velcade Injection)

3.5 mg (per each): $1,923.60

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Injection:

Velcade: 3.5 mg (1 ea)

Generic: 2.5 mg (1 ea); 3.5 mg (1 ea)

Administration: Adult

Note: Reconstituted solution concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose. Consider SUBQ administration in patients with preexisting or at high risk for peripheral neuropathy. Some bortezomib products may not be approved for SUBQ administration; refer to specific product labeling for approved administration routes.

IV: Administer via rapid IV push (3 to 5 seconds). When administering in combination with rituximab for first-line therapy of mantle cell lymphoma, administer bortezomib prior to rituximab.

SUBQ: SUBQ administration of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day treatment cycle has been studied in patients with relapsed multiple myeloma; doses were administered SUBQ (concentration of 2.5 mg/mL) into the thigh or abdomen, rotating the injection site with each dose; injections at the same site within a single cycle were avoided (Ref). Response rates were similar to IV administration; decreased incidence of grade 3 or higher adverse events were observed with SUBQ administration. Administer at least 1 inch from an old site and never administer to tender, bruised, erythematous, or indurated sites. If injection site reaction occurs, the more dilute 1 mg/mL concentration may be used SUBQ (or IV administration of 1 mg/mL concentration may be considered).

For SUBQ or IV administration only; fatalities have been reported with inadvertent intrathecal administration. Bortezomib should NOT be delivered to the patient at the same time with any medications intended for central nervous system administration.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2024 [table 1]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Use: Labeled Indications

Mantle cell lymphoma: Treatment of mantle cell lymphoma in adults.

Multiple myeloma: Treatment of multiple myeloma in adults.

Use: Off-Label: Adult

Antibody-mediated rejection in cardiac transplantation (treatment); Antibody-mediated rejection, kidney transplantation (treatment); Antibody-mediated rejection, liver transplantation (treatment, refractory); Antibody-mediated rejection, lung transplantation (treatment); Cutaneous T-cell lymphoma, mycosis fungoides, relapsed or refractory; Desensitization, kidney transplantation; Follicular lymphoma, relapsed or refractory; Peripheral T-cell lymphoma, relapsed/refractory; Systemic light-chain amyloidosis; Waldenström macroglobulinemia

Medication Safety Issues
Sound-alike/look-alike issues:

Bortezomib may be confused with bosutinib, carfilzomib, ixazomib.

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (chemotherapeutic agent, parenteral and oral) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care, Community/Ambulatory Care, and Long-Term Care Settings).

Administration issues:

The reconstituted concentrations for IV and SUBQ administration are different; use caution when calculating the volume for each route and dose. The manufacturers provide stickers to facilitate identification of the route for reconstituted vials.

For SUBQ or IV administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should NOT be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location away from the separate storage location recommended for intrathecal medications. Bortezomib should NOT be delivered to the patient at the same time with any medications intended for intrathecal administration.

Metabolism/Transport Effects

Substrate of CYP1A2 (Minor), CYP2C19 (Minor), CYP2C9 (Minor), CYP2D6 (Minor), CYP3A4 (Major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Abrocitinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Alfuzosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification

Amisulpride (Oral): May increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Antidiabetic Agents: Bortezomib may increase therapeutic effects of Antidiabetic Agents. Bortezomib may decrease therapeutic effects of Antidiabetic Agents. Risk C: Monitor

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. Risk C: Monitor

Antithyroid Agents: Myelosuppressive Agents may increase neutropenic effects of Antithyroid Agents. Risk C: Monitor

Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Ascorbic Acid: May decrease therapeutic effects of Bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy unless specifically recommended by their care provider. Risk D: Consider Therapy Modification

Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Baricitinib. Risk X: Avoid

BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of BCG Products. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Blood Pressure Lowering Agents: May increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Brincidofovir. Risk C: Monitor

Brivudine: May increase adverse/toxic effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid

Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Chikungunya Vaccine (Live). Risk X: Avoid

Chloramphenicol (Ophthalmic): May increase adverse/toxic effects of Myelosuppressive Agents. Risk C: Monitor

Chloramphenicol (Systemic): Myelosuppressive Agents may increase myelosuppressive effects of Chloramphenicol (Systemic). Risk X: Avoid

Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Cladribine. Risk X: Avoid

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

CloZAPine: Myelosuppressive Agents may increase adverse/toxic effects of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor

Coccidioides immitis Skin Test: Coadministration of Immunosuppressants (Miscellaneous Oncologic Agents) and Coccidioides immitis Skin Test may alter diagnostic results. Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (Inactivated Virus). Risk C: Monitor

COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (mRNA). Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details. Risk D: Consider Therapy Modification

COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of COVID-19 Vaccine (Subunit). Risk C: Monitor

CYP3A4 Inducers (Moderate): May decrease serum concentration of Bortezomib. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of Bortezomib. Risk X: Avoid

CYP3A4 Inhibitors (Moderate): May increase serum concentration of Bortezomib. Risk C: Monitor

CYP3A4 Inhibitors (Strong): May increase serum concentration of Bortezomib. Risk C: Monitor

Deferiprone: Myelosuppressive Agents may increase neutropenic effects of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Risk D: Consider Therapy Modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Dengue Tetravalent Vaccine (Live). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Denosumab: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections. Risk D: Consider Therapy Modification

Deucravacitinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Diazoxide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor

Etrasimod: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Fexinidazole: Myelosuppressive Agents may increase myelosuppressive effects of Fexinidazole. Risk X: Avoid

Filgotinib: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Green Tea: May decrease antineoplastic effects of Bortezomib. Management: Advise patients to avoid concurrent use of green tea extract and other green tea products, particularly at higher doses or amounts, during treatment with bortezomib when possible. Risk D: Consider Therapy Modification

Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Iloperidone: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Inebilizumab. Risk C: Monitor

Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored. Risk D: Consider Therapy Modification

Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Leflunomide. Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents. Risk D: Consider Therapy Modification

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may increase hypotensive effects of Levodopa-Foslevodopa. Risk C: Monitor

Linezolid: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Lormetazepam: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor

Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Multivitamins/Fluoride (with ADE): May decrease therapeutic effects of Bortezomib. Specifically, the vitamin C (ascorbic acid) found in many multivitamins may impair the clinical effects of bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy unless specifically recommended by their care provider. Risk D: Consider Therapy Modification

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease therapeutic effects of Bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy unless specifically recommended by their care provider. Risk D: Consider Therapy Modification

Multivitamins/Minerals (with AE, No Iron): May decrease therapeutic effects of Bortezomib. Specifically, vitamin C may decrease bortezomib therapeutic effects. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy unless specifically recommended by their care provider. Risk D: Consider Therapy Modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Mumps- Rubella- or Varicella-Containing Live Vaccines may increase adverse/toxic effects of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid

Naftopidil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Natalizumab. Risk X: Avoid

Nicergoline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor

Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification

Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ocrelizumab. Risk C: Monitor

Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ofatumumab. Risk C: Monitor

Olaparib: Myelosuppressive Agents may increase myelosuppressive effects of Olaparib. Risk C: Monitor

Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Pholcodine: Blood Pressure Lowering Agents may increase hypotensive effects of Pholcodine. Risk C: Monitor

Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Pidotimod. Risk C: Monitor

Pimecrolimus: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk X: Avoid

Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Pneumococcal Vaccines. Risk C: Monitor

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may increase hypersensitivity effects of Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider Therapy Modification

Promazine: May increase myelosuppressive effects of Myelosuppressive Agents. Risk C: Monitor

Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider Therapy Modification

Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ritlecitinib. Risk X: Avoid

Ropeginterferon Alfa-2b: Myelosuppressive Agents may increase myelosuppressive effects of Ropeginterferon Alfa-2b. Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects. Risk D: Consider Therapy Modification

Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ruxolitinib (Topical). Risk X: Avoid

Silodosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider Therapy Modification

Sphingosine 1-Phosphate (S1P) Receptor Modulators: May increase immunosuppressive effects of Immunosuppressants (Miscellaneous Oncologic Agents). Risk C: Monitor

Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Tacrolimus (Topical). Risk X: Avoid

Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid

Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Tertomotide. Risk X: Avoid

Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Tofacitinib. Risk X: Avoid

Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Typhoid Vaccine. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Ublituximab. Risk C: Monitor

Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may increase immunosuppressive effects of Upadacitinib. Risk X: Avoid

Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Vaccines (Live). Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Vaccines (Non-Live/Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Vaccines (Non-Live/Inactivated/Non-Replicating). Management: Give non-live/inactivated/non-replicating vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before or during therapy should be revaccinated at least 3 months after therapy is complete. Risk D: Consider Therapy Modification

Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Yellow Fever Vaccine. Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Zoster Vaccine (Live/Attenuated): Immunosuppressants (Miscellaneous Oncologic Agents) may increase adverse/toxic effects of Zoster Vaccine (Live/Attenuated). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may decrease therapeutic effects of Zoster Vaccine (Live/Attenuated). Risk X: Avoid

Reproductive Considerations

Evaluate pregnancy status prior to initiating therapy in patients who could become pregnant. Patients who could become pregnant should avoid becoming pregnant during bortezomib treatment and use effective contraception during therapy and for 7 months following bortezomib treatment. Patients with partners who could become pregnant should use effective contraception during and for 4 months following bortezomib treatment.

Bortezomib may potentially affect male or female fertility (based on the mechanism of action).

Pregnancy Considerations

Based on the mechanism of action and on findings in animal reproduction studies, in utero exposure to bortezomib may cause fetal harm.

Breastfeeding Considerations

It is not known if bortezomib is present in breast milk. The manufacturer recommends lactating patients avoid breastfeeding during and for 2 months following bortezomib treatment.

Dietary Considerations

Green tea and green tea extracts may diminish the therapeutic effect of bortezomib and should be avoided (Golden 2009). Avoid grapefruit juice. Avoid additional, nondietary sources of ascorbic acid supplements, including multivitamins containing ascorbic acid (may diminish bortezomib activity) during treatment, especially 12 hours before and after bortezomib treatment (Perrone 2009).

Monitoring Parameters

CBC with differential and platelets (monitor frequently throughout therapy); liver function tests (in patients with existing hepatic impairment); kidney function. Monitor blood glucose (in patients with diabetes). Verify pregnancy status prior to therapy initiation in patients who could become pregnant. Monitor BP. Monitor for signs/symptoms of peripheral neuropathy (consider SUBQ administration in patients with preexisting or at high risk for peripheral neuropathy), dehydration, hypotension (use with caution in patients with dehydration, history of syncope, or taking medications associated with hypotension), posterior reversible leukoencephalopathy syndrome, progressive multifocal leukoencephalopathy, tumor lysis syndrome, or hyper-/hypoglycemia. Monitor baseline chest x-ray and then periodic pulmonary function testing (with new or worsening pulmonary symptoms). Monitor closely in patients with risk factors for heart failure or existing heart disease.

The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.

Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017], (ESC [Lyon 2022]). Assess BP at baseline and each clinical visit (also consider weekly home monitoring for initial 3 months, then monthly thereafter); assess natriuretic peptide at baseline for high and very high-risk patients and consider at each cycle for the first 6 cycles; consider checking natriuretic peptide at baseline for low- and moderate-risk patients; obtain a baseline echocardiography in all patients (ESC [Lyon 2022]).

Mechanism of Action

Bortezomib inhibits proteasomes, enzyme complexes which regulate protein homeostasis within the cell. Specifically, it reversibly inhibits chymotrypsin-like activity at the 26S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: ~498 to 1,884 L/m2; distributes widely to peripheral tissues.

Protein binding: ~83%.

Metabolism: Hepatic primarily via CYP2C19, CYP3A4, and CYP1A2 and to a lesser extent CYP2D6 and CYP2C9; forms metabolites (inactive) via deboronization followed by hydroxylation.

Half-life elimination: Single dose: IV: 9 to 15 hours; Multiple dosing: 1 mg/m2: 40 to 193 hours; 1.3 mg/m2: 76 to 108 hours.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: Dose-normalized mean AUC levels were increased by ~60% in patients with moderate or severe hepatic impairment.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Bortezomib spc | Bortezon | Veelbore;
  • (AR) Argentina: Biliodim | Borater | Bortezomib everex | Bortezomib Sandoz | Bortmex | Bozob | Bromadene | Egidon | Eugene | Gysaty | Miasoma | Multizom | Ninib | Simbiote | Velcade | Zefra;
  • (AT) Austria: Bortezomib accord | Bortezomib hcs | Bortezomib Hikma | Bortezomib mylan | Velcade;
  • (AU) Australia: Bortezom | Bortezomib accord | Bortezomib juno | Bortezomib Sandoz | Dbl bortezomib | Velcade;
  • (BE) Belgium: Bortezomib ab | Bortezomib accord | Bortezomib fresenius kabi | Bortezomib mylan | Bortezomib reddy | Bortezomib Sandoz | Bortezomib teva | Velcade;
  • (BG) Bulgaria: Bortega | Bortezocon | Bortezomib actavis | Bortezomib Sandoz | Vortemyel;
  • (BR) Brazil: Bormib | Bortezomibe | Bortezomibe blau | Bortyz | Bozored | Mibo | Mielocade | Tovar | Velcade | Verazo | Zomi | Zomyle;
  • (CH) Switzerland: Bortezomib accord | Bortezomib Sandoz | Bortezomib zentiva;
  • (CI) Côte d'Ivoire: Egybort;
  • (CL) Chile: Bicavan | Bozix | Bozob;
  • (CN) China: Velcade;
  • (CO) Colombia: Belocef | Borteleg | Bortemix | Borten | Bortesun | Bortezomib Sandoz | Bortezomseven | Botemib | Bozib | Egidon | Fizomeb | Mibzo | Nubortez | Porix | Rebtyk | Tebide | Tenimib | Tizob | Unitezo | Velcade | Vortyz | Zomitec;
  • (CZ) Czech Republic: Bortega | Bortezomib accord | Bortezomib actavis | Bortezomib adamed | Bortezomib ebewe | Bortezomib fresenius kabi | Bortezomib glenmark | Bortezomib zentiva | Zegomib;
  • (DE) Germany: Bortezom accord bb farma | Bortezomib accord | Bortezomib beta | Bortezomib cipla | Bortezomib denk | Bortezomib hexal | Bortezomib Hikma | Bortezomib hospira | Bortezomib medac | Bortezomib mylan | Bortezomib puren | Bortezomib ratiopharm | Bortezomib ribosepharm | Bortezomib sun | Bortezomib zentiva | Velcade;
  • (DO) Dominican Republic: Velcade | Votobel;
  • (EC) Ecuador: Borten | Bortesun | Botemib | Bozob | Kerba | Miasoma | Mibzo | Velcade;
  • (EE) Estonia: Bortezomib accord | Bortezomib actavis | Bortezomib fresenius kabi | Bortezomib hospira | Bortezomib sun | Bortezomib teva | Velcade;
  • (EG) Egypt: Bortezomib intas | Velcade;
  • (ES) Spain: Bortezomib accord | Bortezomib aurovitas | Bortezomib cipla | Bortezomib dr. reddys | Bortezomib farmoz | Bortezomib fresenius kabi | Bortezomib kern | Bortezomib krka | Bortezomib mylan | Bortezomib sun | Bortezomib teva | Bortezomib tillomed | Velcade;
  • (ET) Ethiopia: Bortenat | Bortezomib msn;
  • (FI) Finland: Bortezomib reddy | Bortezomib sun | Bortezomib viatris | Velcade;
  • (FR) France: Bortezomib ohre pharma | Bortezomib reddy pharma | Bortezomib viatris | Bortezomib zentiva | Velcade;
  • (GB) United Kingdom: Bortezomib accord | Bortezomib milpharm | Bortezomib mylan | Bortezomib reddys | Bortezomib Sandoz | Bortezomib sun | Velcade;
  • (GR) Greece: Velcade;
  • (HR) Croatia: Bortezomib pliva | Velcade;
  • (HU) Hungary: Bortezomib accord | Bortezomib actavis | Bortezomib msn | Bortezomib Sandoz | Bortezomib teva | Velcade | Vortemyel | Zegomib;
  • (ID) Indonesia: Bormib | Bortecade | Borteloma | Bortero | Velcade;
  • (IE) Ireland: Bortezomib accord | Bortezomib krka | Bortezomib rowex;
  • (IN) India: Biocure | Bortecad | Bortemib | Bortenat | Bortero | Bortesam | Bortetor | Bortetrust | Bortezom | Bortiad | Bortirel | Bortrac | Borviz | Egybort | Jupizomib | Mibor | Myezom | Mylosome | MyZomib | Ortez | Proteoz | Rolcade | Velcade | Zomib | Zortemib;
  • (IT) Italy: Bortezomib aurobindo | Bortezomib fresenius kabi | Bortezomib Hikma | Bortezomib medac | Bortezomib mylan | Bortezomib reddys | Bortezomib sun | Bortezomib teva | Bortezomib zentiva | Velcade;
  • (JO) Jordan: Brotex | Veelbore;
  • (JP) Japan: Bortezomib dsep | Bortezomib sawai | Bortezomib towa | Bortezomib yakult | Velcade;
  • (KE) Kenya: Bortemib | Bortesun | Bortimore | Velcade;
  • (KR) Korea, Republic of: Belzomib | Bortevel | Protezomib | Tezobel | Tezobell | Tezomin | Velcade | Velkin | Velzomib;
  • (KW) Kuwait: Velcade;
  • (LB) Lebanon: Borcade | Velcade;
  • (LT) Lithuania: Bortezomib accord | Bortezomib fresenius kabi | Bortezomib sun | Sangrel | Vortemyel;
  • (LV) Latvia: Bortezomib accord | Bortezomib fresenius kabi | Bortezomib sun | Velcade | Vortemyel;
  • (MA) Morocco: Velcade;
  • (MX) Mexico: Bemoncaz | Bizmi | Bomib | Elomaziv | Exfucikanet | Misecade | Rebtyk | Velcade | Zuricade;
  • (MY) Malaysia: Accord bortezomib | Bortero | Myborte | Retrox | Velcade;
  • (NL) Netherlands: Bortezomib accord | Bortezomib adamed | Bortezomib B-medical | Bortezomib fresenius kabi | Bortezomib krka | Bortezomib msn | Bortezomib reddy | Bortezomib Sandoz | Bortezomib sun | Bortezomib zentiva | Velcade;
  • (NO) Norway: Bortezomib accord | Bortezomib mylan | Velcade;
  • (NZ) New Zealand: Bortezomib dr. reddys | Bortezomib juno | Dbl bortezomib | Velcade;
  • (PE) Peru: Bortesun | Bortzo | Botemib | Bozob | Egybort | Mibor | Topneuter | Velcade | Velcord;
  • (PH) Philippines: Bezom | Biomib | Bortesum | Bortether | Mylocure | Pfizer bortezomib | Velcade | Zyocade;
  • (PK) Pakistan: Bortezomib pharmidea | Egybort;
  • (PL) Poland: Bortezomib accord | Bortezomib actavis | Bortezomib adamed | Bortezomib aurovitas | Bortezomib fresenius kabi | Bortezomib medac | Bortezomib sun | Velcade | Vortemyel;
  • (PR) Puerto Rico: Velcade;
  • (PT) Portugal: Bortezomib accord | Bortezomib fresenius kabi | Bortezomib generis | Bortezomib krka | Bortezomib tecnigen | Bortezomib teva | Velcade;
  • (PY) Paraguay: Borater | Bortezomib bauel top | Bortezomib bioteng | Bortezomib catedral | Bortezomib cellofarm | Bortezomib gemepe | Bortezomib imedic | Bortezomib indufar | Bortezomib libra | Bortezomib prosalud | Bortezomib Sandoz | Botemib | Bozob;
  • (QA) Qatar: Bortada | Velcade | Velzome;
  • (RO) Romania: Bortega | Bortezomib accord | Bortezomib actavis | Bortezomib glenmark | Bortezomib hospira | Bortezomib reddys | Bortezomib Sandoz | Bortezomib sun | Bortezomib zentiva | Vortemyel;
  • (RU) Russian Federation: Bartizar | Boramilan | Boramilan fs | Bortezol | Bortezomib canon | Bortezomib teva | Milanfore | Milatib | Myborte | Velcade | Velmib | Verozomib;
  • (SA) Saudi Arabia: Bortezomib spc | Valtroza | Veelbore;
  • (SE) Sweden: Bortezomib avansor | Bortezomib fresenius kabi | Bortezomib krka | Bortezomib medac | Bortezomib mylan | Bortezomib reddy | Bortezomib sun | Bortezomib teva | Velcade;
  • (SG) Singapore: Velcade;
  • (SI) Slovenia: Bortezomib accord | Bortezomib actavis | Bortezomib mylan | Bortezomib Sandoz | Bortezomib teva | Gloftrinid | Velcade;
  • (SK) Slovakia: Bortega | Bortezomib accord | Bortezomib actavis | Bortezomib glenmark | Bortezomib mylan | Bortezomib pharmevid | Bortezomib Sandoz | Velcade | Zegomib;
  • (TH) Thailand: Bortero | Bortezomib Alvogen | Bortezomib kabi | Borviz | Mibzo | Myborte | Tevazomib | Velcade;
  • (TN) Tunisia: Bortezomib neapoli | Velcade;
  • (TR) Turkey: Biemib | Boractib | Borcade | Velcade | Veltezo;
  • (TW) Taiwan: Velcade;
  • (UA) Ukraine: Bortenat | Bortero | Bortezomib Alvogen | Bortezovista | Brecer | Mozetrox | Namibor;
  • (UG) Uganda: Mibzo;
  • (UY) Uruguay: Botemib;
  • (VE) Venezuela, Bolivarian Republic of: Botemib;
  • (ZA) South Africa: Bertred | Bortiv | Bortrac | Valoma | Valtib
  1. Agathocleous A, Rohatiner A, Rule S, et al. Weekly Versus Twice Weekly Bortezomib Given in Conjunction With Rituximab, in Patients With Recurrent follicular Lymphoma, Mantle Cell Lymphoma and Waldenström Macroglobulinaemia. Br J Haematol. 2010;151(4):346-353. [PubMed 20880120]
  2. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. [PubMed 27918725]
  3. Andre P, Cisternino S, Chiadmi F, et al. Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial. Ann Pharmacother. 2005;39(9):1462-1466. [PubMed 15985470]
  4. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival Analysis of a Randomized, Phase 3 Study of Subcutaneous versus Intravenous Bortezomib in Patients With Relapsed Multiple Myeloma. Haematologica. 2012;97(12):1925-1928. [PubMed 22689676]
  5. Baradaran H, Dashti-Khavidaki S, Taher M, Talebian M, Nasiri-Toosi M, Jafarian A. Antibody-mediated rejection in adult liver transplant recipients: a case series and literature review. J Clin Pharmacol. 2022;62(2):254-271. doi:10.1002/jcph.1963 [PubMed 34480762]
  6. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176-185. doi:10.1111/j.1365-2141.2007.06639.x [PubMed 17593024]
  7. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  8. Bortezomib 1 or 2.5 mg injection [prescribing information]. Lake Forest, IL: Hospira Inc; December 2022.
  9. Bortezomib 3.5 mg injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2022.
  10. Bortezomib for Injection 3.5 mg (13.5 mL) lyophilized powder vial [product monograph]. Toronto, Ontario, Canada: Teva Canada; December 2022.
  11. Boruzu (bortezomib) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; September 2024.
  12. Bringhen S, Larocca A, Rossi D, et al. Efficacy and Safety of Once-Weekly Bortezomib in Multiple Myeloma Patients. Blood. 2010;116(23):4745-4753. [PubMed 20807892]
  13. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020;7(11):e827-e837. doi:10.1016/S2352-3026(20)30224-6 [PubMed 33091356]
  14. Cavo M, Pantani L, Petrucci MT, et al; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9-19. doi:10.1182/blood-2012-02-408898 [PubMed 22498745]
  15. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085. doi:10.1016/S0140-6736(10)61424-9 [PubMed 21146205]
  16. Chan KM, Lee CS, Wu TJ, Lee CF, Chen TC, Lee WC. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation. 2011;91(5):e29-e30. doi:10.1097/TP.0b013e318208138c [PubMed 21336085]
  17. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and Safety of Bortezomib in Multiple Myeloma Patients With Advanced Renal Failure: A Multicenter Retrospective Study. Blood. 2006;109(9):2604-2606. [PubMed 17138816]
  18. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. J Clin Oncol. 2008;26(29):4784-4790. [PubMed 18711175]
  19. Chen CI, Kouroukis CT, White D, et al. Bortezomib is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570-1575. doi:10.1200/JCO.2006.07.8659 [PubMed 17353550]
  20. Colvin MM, Cook JL, Chang P, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131(18):1608-1639. [PubMed 25838326]
  21. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23-31. doi:10.1111/j.1600-0609.2010.01533.x [PubMed 20874823]
  22. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276-3782. doi:10.1182/blood-2013-05-503862 [PubMed 24004667]
  23. Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. J Clin Oncol. 2009;27(36):6086-6093. [PubMed 19858394]
  24. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544-1557. [PubMed 26976420]
  25. Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-X [PubMed 28017406]
  26. Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53. doi:10.1038/s41408-020-0311-8 [PubMed 32393732]
  27. Eskandary F, Bond G, Schwaiger E, et al. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 2014;15:107. doi:10.1186/1745-6215-15-107 [PubMed 24708575]
  28. Eskandary F, Regele H, Baumann L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2018;29(2):591-605. doi:10.1681/ASN.2017070818 [PubMed 29242250]
  29. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  30. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol. 2006;24(30):4867-4874. [PubMed 17001068]
  31. Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation. 2010;90(12):1486-1492. doi:10.1097/TP.0b013e3181fdd9b0 [PubMed 21042239]
  32. Fowler N, Kahl BS, Lee P, et al. Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. J Clin Oncol. 2011;29(25):3389-3395. [PubMed 21810687]
  33. Fraunfelder FW, Yang HK. Association Between Bortezomib Therapy and Eyelid Chalazia. JAMA Ophthalmol. 2016;134(1):88-90. doi:10.1001/jamaophthalmol.2015.3963 [PubMed 26469392]
  34. Friedberg JW, Vose JM, Kelly JL, et al. The Combination of Bendamustine, Bortezomib, and Rituximab for Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma. Blood. 2011;117(10):2807-2812. [PubMed 21239695]
  35. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422-1428. doi:10.1200/JCO.2009.25.3237 [PubMed 20142586]
  36. Gilbar PJ, Seger AC. Fatalities Resulting From Accidental Intrathecal Administration of Bortezomib: Strategies for Prevention. J Clin Oncol. 2012;30(27):3427-3428. [PubMed 22851559]
  37. Golden EB, Lam PY, Kardosh A, et al. Green Tea Polyphenols Block the Anticancer Effects of Bortezomib and Other Boronic Acid-Based Proteasome Inhibitors. Blood. 2009;113(23):5927-5937. [PubMed 19190249]
  38. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520-525. doi:10.1093/annonc/mdn656 [PubMed 19074748]
  39. Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471 [PubMed 33939491]
  40. Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563-1573. doi:10.1016/S0140-6736(20)32292-3 [PubMed 33189178]
  41. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib Plus Dexamethasone is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone as Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. J Clin Oncol. 2010;28(30):4621-4629. [PubMed 20823406]
  42. Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
  43. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757 [PubMed 32716741]
  44. Iwamoto T, Ishibashi M, Fujieda A, et al. Drug Interaction Between Itraconazole and Bortezomib: Exacerbation of Peripheral Neuropathy and Thrombocytopenia Induced by Bortezomib. Pharmacotherapy. 2010;30(7):661-665. [PubMed 20575631]
  45. Jacobson JO, Polovich M, McNiff KK, et al. American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards. J Clin Oncol. 2009;27(32):5469-5475. [PubMed 19786650]
  46. Jagannath S, Barlogie B, Berenson JR, et al .Bortezomib in Recurrent and/or Refractory Multiple Myeloma; Initial Clinical Experience in Patients With Impaired Renal Function. Cancer. 2005;103(6):1195-1200. [PubMed 15690325]
  47. Jeong JC, Jambaldorj E, Kwon HY, et al. Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. Medicine (Baltimore). 2016;95(5):e2635. doi:10.1097/MD.0000000000002635 [PubMed 26844479]
  48. Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252-3260. doi:10.1200/JCO.20.01285 [PubMed 32730181]
  49. Kastritis E, Palladini G, Minnema MC, et al; ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46-58. doi:10.1056/NEJMoa2028631 [PubMed 34192431]
  50. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. J Clin Oncol. 2010;28(6):1031-1037. [PubMed 20085941]
  51. Khan ML, Reeder CB, Kumar SK, et al. A Comparison of Lenalidomide/Dexamethasone versus Cyclophosphamide/Lenalidomide/Dexamethasone versus Cyclophosphamide/Bortezomib/Dexamethasone in Newly Diagnosed Multiple Myeloma. Br J Haematol. 2012;156(3):326-333. [PubMed 22107129]
  52. Kim DG, Lee J, Park Y, et al. Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study. BMC Nephrol. 2019;20(1):456. doi:10.1186/s12882-019-1625-2 [PubMed 31818254]
  53. Kolonko A, Słabiak-Błaż N, Karkoszka H, Więcek A, Piecha G. The preliminary results of bortezomib used as a primary treatment for an early acute antibody-mediated rejection after kidney transplantation-a single-center case series. J Clin Med. 2020;9(2):529. doi:10.3390/jcm9020529 [PubMed 32075220]
  54. Koslik MA, Friebus-Kardash J, Heinemann FM, Kribben A, Bräsen JH, Eisenberger U. Differential treatment effects for renal transplant recipients with DSA-positive or DSA-negative antibody-mediated rejection. Front Med (Lausanne). 2022;9:816555. doi:10.3389/fmed.2022.816555 [PubMed 35174191]
  55. Kropff M, Bisping G, Schuck E, et al; Deutsche Studiengruppe Multiples Myelom. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138(3):330-337. doi:10.1111/j.1365-2141.2007.06656.x [PubMed 17614819]
  56. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375-4382. doi:10.1182/blood-2011-11-395749 [PubMed 22422823]
  57. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. Ann Hematol. 2011;90(2):201-206. [PubMed 20821326]
  58. Leal TB, Remick SC, Takimoto CH, et al. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol. 2011;68(6):1439-1447. [PubMed 21479634]
  59. LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and Safety of Bortezomib in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18(10):2954-2963. doi:10.1158/1078-0432.CCR-11-2873 [PubMed 22394984]
  60. Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014;123(7):985-991. doi:10.1182/blood-2013-08-521468 [PubMed 24227817]
  61. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 [PubMed 36017568]
  62. Mateos MV, Dimopoulos MA, Cavo M, et al; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518-528. doi:10.1056/NEJMoa1714678 [PubMed 29231133]
  63. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-up and Impact of Subsequent Therapy in the Phase III VISTA Trial. J Clin Oncol. 2010;28(13):2259-2266. [PubMed 20368561]
  64. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228-1263. doi:10.1200/JCO.18.02096 [PubMed 30932732]
  65. Mikhael JR, Belch AR, Prince HM, et al. High Response Rate to Bortezomib With or Without Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Results of a Global Phase 3b Expanded Access Program. Br J Haematol. 2009;144(2):169-175. [PubMed 19036114]
  66. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394. doi:10.1182/blood-2011-11-390930 [PubMed 22331188]
  67. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [published correction appears in Lancet. Lancet. 2019;394(10192):29-38. doi:10.1016/S0140-6736(19)31240-1 [PubMed 31171419]
  68. Moreau P, Coiteux V, Hulin C, et al. Prospective Comparison of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma. Haematologica. 2008;93(12):1908-1911. [PubMed 18768528]
  69. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569-2574. doi:10.1182/blood-2016-01-693580 [PubMed 27002117]
  70. Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823-829. doi:10.1007/s40262-012-0010-0 [PubMed 23018466]
  71. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Relapsed Multiple Myeloma: A Randomised, Phase 3, Non-Inferiority Study. Lancet Oncol. 2011;12(5):431-440. [PubMed 21507715]
  72. Neuhaus K, Hohlfelder B, Bollinger J, Haug M 3rd, Torbic H. Antibody-mediated rejection management following lung transplantation. Ann Pharmacother. 2022;56(1):60-64. doi:10.1177/10600280211012410 [PubMed 33899550]
  73. Neumann J, Tarrasconi H, Bortolotto A, et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation. 2010;89(1):125-126. doi:10.1097/TP.0b013e3181c280f9 [PubMed 20061929]
  74. O'Connor OA, Wright J, Moskowitz C, et al. Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. J Clin Oncol. 2005;23(4):676-684. [PubMed 15613699]
  75. O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222-230. doi:10.1111/bjh.15261 [PubMed 29740809]
  76. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901. [PubMed 17679727]
  77. Ovesen JL, Sammons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
  78. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101-5109. doi:10.1200/JCO.2010.29.8216 [PubMed 20940200]
  79. Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-766. doi:10.1056/NEJMoa160 [PubMed 27557302]
  80. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant. 2012;12(9):2526-2531. doi:10.1111/j.1600-6143.2012.04126.x [PubMed 22681986]
  81. Pekol T, Daniels JS, Labutti J, et al. Human Metabolism of the Proteasome Inhibitor Bortezomib: Identification of Circulating Metabolites. Drug Metab Dispos. 2005;33(6):771-777. [PubMed 15764713]
  82. Perrone G, Hideshima T, Ikeda H, et al. Ascorbic Acid Inhibits Activity of Bortezomib in vivo. Leukemia. 2009;23(9):1679-1686. [PubMed 19369963]
  83. Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA. Differential effect of bortezomib on HLA class I and class II antibody. Transplantation. 2014;98(6):660-665. doi:10.1097/TP.0000000000000132 [PubMed 24798311]
  84. Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?. Acta Haematol. 2011;126(3):163-168. doi:10.1159/000328417 [PubMed 21778706]
  85. Pratt G, El-Sharkawi D, Kothari J, et al; Diagnosis and management of Waldenström macroglobulinaemia- a British Society for Haematology guideline. Br J Haematol. 2022;197(2):171-187. doi:10.1111/bjh.18036 [PubMed 35020191]
  86. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and Safety of Once-Weekly and Twice-Weekly Bortezomib in Patients With Relapsed Systemic AL Amyloidosis: Results of a Phase 1/2 Study. Blood. 2011;118(4):865-873. doi:10.1182/blood-2011-02-334227 [PubMed 21562045]
  87. Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014;124(16):2498-2506. doi:10.1182/blood-2014-04-568329 [PubMed 25202139]
  88. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341. doi:10.1038/leu.2009.26 [PubMed 19225538]
  89. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416-3417. doi:10.1182/blood-2010-02-271676 [PubMed 20413666]
  90. Refer to manufacturer's labeling.
  91. Richardson PG, Oriol A, Beksac M, et al; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781-794. doi:10.1016/S1470-2045(19)30152-4 [PubMed 31097405]
  92. Richardson PG, Sonneveld P, Schuster M, et al. Extended Follow-up of a Phase 3 Trial in Relapsed Multiple Myeloma: Final Time-to-Event Results of the APEX Trial. Blood. 2007;110(10):3557-3560. [PubMed 17690257]
  93. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of Symptomatic Peripheral Neuropathy With Bortezomib in the Phase III APEX Trial in Relapsed Multiple Myeloma: Impact of a Dose-Modification Guideline. Br J Haematol. 2009;144(6):895-903. [PubMed 19170677]
  94. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2005;352(24):2487-249824429336 [PubMed 15958804]
  95. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686. doi:10.1182/blood-2010-02-268862 [PubMed 20385792]
  96. Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123(10):1461-1469. doi:10.1182/blood-2013-07-517276 [PubMed 24429336]
  97. Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944-953. doi:10.1056/NEJMoa1412096 [PubMed 25738670]
  98. Robak T, Jin J, Pylypenko H, et al; LYM-3002 investigators. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(11):1449-1458. doi:10.1016/S1470-2045(18)30685-5 [PubMed 30348538]
  99. Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119-v133. doi:10.1093/annonc/mdw270 [PubMed 27664248]
  100. Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337-1345. doi:10.1182/blood.2019000241 [PubMed 31484647]
  101. Rosiñol L, Oriol A, Teruel AI, et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589-1596. doi:10.1182/blood-2012-02-408922 [PubMed 22791289]
  102. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32(25):2712-2717. doi:10.1200/JCO.2013.54.8164 [PubMed 25024076]
  103. Sadaka B, Ejaz NS, Shields AR, et al. A Banff Component Scoring-based histologic assessment of bortezomib-based antibody-mediated rejection therapy. Transplantation. 2015;99(8):1691-1699. doi:10.1097/TP.0000000000000694 [PubMed 25803498]
  104. San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31(4):448-455. doi:10.1200/JCO.2012.41.6180 [PubMed 23233713]
  105. Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N; ADDIKD Guideline Working Group. International consensus guideline for anticancer drug dosing in kidney dysfunction 2022. https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction. Published 2022. Accessed October 23, 2023. [PubMed Sandu.1]
  106. Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1600-1609. doi:10.1200/JCO.21.02734 [PubMed 36413710]
  107. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J Clin Oncol. 2012;30(24):2946-2955. doi:10.1200/JCO.2011.39.6820 [PubMed 22802322]
  108. Stuckey LJ, Kamoun M, Chan KM. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Ann Pharmacother. 2012;46(1):e2. doi:10.1345/aph.1Q509 [PubMed 22202499]
  109. Taro-Bortezomib (bortezomib for injection) [product monograph]. Brampton, Ontario, Canada: Taro Pharmaceuticals Inc; October 2021.
  110. Timofeeva OA, Choe J, Alsammak M, et al. Guiding therapeutic plasma exchange for antibody-mediated rejection treatment in lung transplant recipients - a retrospective study. Transpl Int. 2021;34(4):700-708. doi:10.1111/tri.13825 [PubMed 33469943]
  111. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. J Clin Oncol. 2009;27(23):3830-3835. doi:10.1200/JCO.2008.20.4677 [PubMed 19506160]
  112. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  113. United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
  114. Uttamsingh V, Lu C, Miwa G, et al. Relative Contributions of the Five Major Hyman Cytochromes P450, 1A2, 2C9, 2C19, and 3A4, to the Hepatic Metabolism of the Proteosome Inhibitor Bortezomib. Drug Metab Dispos. 2005;33(11):1723-1728. [PubMed 16103134]
  115. Vacha M, Chery G, Hulbert A, et al. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: does it work? Clin Transplant. 2017;31(3). doi:10.1111/ctr.12886 [PubMed 27988971]
  116. Vanderloo JP, Pomplun ML, Vermeulen LC, et al. Stability of Unused Reconstituted Bortezomib in Original Manufacturer Vials. J Oncol Pharm Pract. 2011;17(4):400-402. [PubMed 20926455]
  117. Velcade (bortezomib) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; August 2022.
  118. Velcade (bortezomib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; February 2022.
  119. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-4390. doi:10.1182/blood-2011-10-388462 [PubMed 22331187]
  120. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. doi:10.1182/blood.2020005288 [PubMed 32325490]
  121. Waiser J, Budde K, Schütz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant. 2012;27(3):1246-1251. doi:10.1093/ndt/gfr465 [PubMed 21852274]
  122. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010;89(3):277-284. doi:10.1097/TP.0b013e3181c6ff8d [PubMed 20145517]
  123. Woodle ES, Shields AR, Ejaz NS, et al. Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant. 2015;15(1):101-118. doi:10.1111/ajt.13050 [PubMed 25534446]
  124. Zinzani PL, Musuraca G, Tani M, et al. Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma. J Clin Oncol. 2007;25(27):4293-4297. [PubMed 17709797]
Topic 8509 Version 469.0